title: [Rofecoxib (Vioxx) has been withdrawn, what next?].
authors.affiliation: Lääketieteen tiedejärjestöjen kansainvälinen neuvosto (CIOMS), c/o World Health Organization, Geneva, Switzerland. idanpaanj@who.int
authors.forename: Juhana E
authors.initials: JE
authors.lastname: Idänpään-Heikkilä
authors.forename: Timo
authors.initials: T
authors.lastname: Klaukka
mesh_terms: D004305:Dose-Response Relationship, Drug; D004335:Drug and Narcotic Control; D005387:Finland; D005544:Forecasting; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D018570:Risk Assessment; D020521:Stroke / Q000139:chemically induced* / Q000453:epidemiology; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use; D028761:Withholding Treatment
chemical_list: D007783:Lactones; D013450:Sulfones; C116926:rofecoxib